Executive Vice President and Chief Scientific Officer Sosei Group June 2015 – Present (1 year) Sosei is a biopharmaceutical company originating from Japan but with global presence. Sosei's primary business model is based on identifying novel and/or differentiated product assets or technology platforms. Through supporting these in preclinical and clinical development and establishing commercial partnerships, Sosei advances new medicines to patients worldwide. Chief Scientific Officer and Founder Heptares Therapeutics 2006 – Present (10 years)Welwyn Garden City Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Cubist, Morphosys and Takeda. Heptares is a wholly owned subsidiary of Sosei Group Corporation. To learn more about Heptares, please visit www.heptares.com (Open)4 honors and awards Visiting Lecturer University of Cambridge 2002 – 2006 (4 years)Deptartments of Pharmacology and Chemical Engineeering Lecturer to Part II undergraduate pharmacology students in Drug discovery. Module co-ordinator for 3 modules – ‘Treating Disease’, Drug Discovery and Biotherapeutics for Bioscience Enterprise Masters course. Lecturer in Genomics and Personalised Medicine to Medical students Invited lecturer in Functional genomics at University of York. Corporate Industrial advisor to University of Sheffield advising on course content and structure and academic/commercial collaborations. Independent Consultant to Venture Capital and Biotech companies F.H.Marshall Consultancy 2002 – 2006 (4 years) Independent consultant for wide range of Pharmaceutical, Biotech and Venture Capital companies. Providing strategic and scientific advice on drug discovery, pharmacology and technology. Non-executive director CellAura Member of Scientific Advisory Boards of Abingworth, Paradigm, Inpharmatica Biofocus, Oxagen, Sentinel and Merlion. Consultant to Venture Capital companies including Abingworth, Advent International, Mizuho, MVM and Cambridge Gateway. Consultant to MRC, Shire, Cancer Research Technologies, Chroma, Amura Ltd (previously Proteom), Galapagos, Biovitrum, BioImage, Novasite, Celltech, Millennium Director Biology Europe Millennium Pharmaceuticals 2000 – 2002 (2 years)Cambridge, United Kingdom Recruited to build a Drug Discovery Biology function for Millennium in Europe from scratch. The UK site was involved in Millennium’s Oncology drug discovery with an emphasis on kinase targets. Responsible for lead optimisation biology on oncology targets from HTS to clinical trials. Head of Molecular Pharmacology GSK 1998 – 2000 (2 years)Stevenage, United Kingdom The Department consisted of 75 multidisciplinary scientists who focussed on different protein classes. The Departement included units working on GPCRs, Ion channels, Integrins and Proteases. Head of Receptor Systems Unit GlaxoWellcome 1995 – 1998 (3 years)Stevenage, United Kingdom The Unit was responsible for GPCR research in GlaxoWellcome UK and had a high success rate in contributing to Drug Discovery projects. The group had a high academic profile, demonstrated by an extensive publication list including cloning of the GABAB receptor, first demonstration of GPCR heterodimerisation, cloning of the CGRP and adrenomedullin receptors, identification of the RAMP proteins, de-orphanning of GPR41, GPR43 and the nicotinic acid receptor. Team Leader Neuropharmacology Glaxo 1989 – 1994 (5 years)Ware, Hertfordshire, UK Group leader working on disease areas including epilepsy, sleep, anxiety, pain and Alzheimer’s disease.